Clay Siegall Of Seattle Genetics Shares A Couple Of The Latest Science Articles

Home | Chemotherapy | Clay Siegall Of Seattle Genetics Shares A Couple Of The Latest Science Articles

Sharing news about the latest in the world of science, CEO Clay Siegall posted on his blog about problems regarding a recent pox virus research development. A scientist at the University of Alberta synthesized horsepox in their lab which is under criticism. While he claims that he did so because this was the only way to study it critics say that he did so because he has a profit motive. He could have obtained a horsepox sample out in the wild without too much work but it is suspected he created it instead so that the company he is working with could commercialize his lab-created horsepox instead.

In another article about the current flu vaccine, Clay Siegall posted an NPR article saying that it provides the best protection available for younger people. While it’s not as effective as past versions have been it has still prevented potentially thousands of kids from getting sick and many lives as well. The CDC estimates that it’s about 36% effective this year and younger people are better protected than older people are.

Seattle Genetics is a Seattle area biotech firm that was co-founded by Clay Siegall. His company develops drugs to treat cancer using antibody drug conjugates (ADC). He is one of the world’s foremost authorities on ADCs as he has been researching them for over 20 years. He is passionate about providing cures for patients who have cancer which he says is the reason he is enthusiastic to get out of bed every day.

After earning a Ph.D. in genetics, Clay Siegall went to work at the National Cancer Institute. He was a Biotechnology Fellow and Staff Fellow for this federal government department. Next he joined Bristol-Myers Squibb as a Senior Research Investigator at the Pharmaceutical Research Institute in Seattle.

As CEO of Seattle Genetics, he sets the strategy of the company. As part of this he has signed strategic partnerships with some of the biggest pharmaceutical companies in the world like AbbVie and GlaxoSmithKline. These partnerships supply the funds his company needs to carry out their research on ADCs, of which they have 20 in multiple stages of development.